Read More

Citius Pharmaceuticals Announces Collaboration With The University Of Pittsburgh To Evaluate T-reg Cell Depletion With I/ONTAK In Combination With Pembrolizumab In Recurrent Or Metastatic Solid Cancer Tumors In A Phase 1 Investigator-Initiated Trial

I/ONTAK plus PD-1 checkpoint inhibitor pembrolizumab to be evaluated in solid tumor patients University of Pittsburgh dose-ranging study expected to begin in the fourth quarter of 2022 Collaboration marks second

CTXR